Study finds excellent agreement between subjective and objective compliance with OAT
Patients with obtrusive sleep apnea experience high rates of therapy compliance
2011-06-14
(Press-News.org) DARIEN, Ill. – According to new research that will be presented Saturday, June 11, at the 20th Anniversary Meeting of the American Academy of Dental Sleep Medicine (AADSM), objective compliance measurements agree with subjective compliance estimates in patients with obstructive sleep apnea (OSA) undergoing oral appliance therapy (OAT) – a finding that is not apparent in patients using continuous positive airway pressure (CPAP) therapy.
Results show that the objective mean wearing time in the whole group was 6.8 hours per night. Among 21 patients who filled out the subjective compliance diary, both the objective and subjective mean wearing times were 7.0 hours per night.
"The results of this study suggest that the use of an objective instrument to measure oral appliance compliance during treatment of obstructive sleep apnea is feasible and, therefore, should be implemented in future studies dealing with oral appliance therapy for obstructive sleep apnea," said principal investigator and lead author Olivier M. Vanderveken, MD, PhD, a staff-member consultant ENT, head and neck surgeon at the Antwerp University Hospital, and faculty lecturer at the Faculty of Medicine of the University of Antwerp in Belgium.
"These results contrast with the finding in literature on compliance during CPAP treatment revealing that self-reported daily compliance with CPAP significantly overestimates the actual daily use of CPAP as assessed by objective measurement of CPAP compliance," said Vanderveken.
This four-week clinical trial compared active measurement of Mandibular Repositioning Appliance (MRA) compliance with patients' self-reports. The study involved 23 men and women with an established diagnosis of sleep-disordered breathing (SDB) who had an average apnea-hypopnea index (AHI) of 14.8 breathing pauses per hour of sleep. They had an average age of 47 years. Compliance was measured during MRA treatment by establishing a mean rate of use, using an active built-in microsensor thermometer (TheraMon®) with on-chip integrated read-out electronics. The sampling interval of the recording by the active microsensor was done at a rate of 1 measurement per 15 minutes (every 900 seconds). The subjects were unaware that their MRA use was being measured objectively.
The read-out of the data was performed at a one-month interval. During the follow-up visit, patients were asked to fill out a questionnaire about MRA wear during the last four weeks (mean hours/night, mean nights/week). The objective measurement of MRA wear time was based on the assumption that the MRA has been worn when the chip records a temperature intraorally > 89.6 °F. To compare the subjective estimates of the patients with the objective data from the microsensor, a Wilcoxon signed rank test was performed.
"The removable nature of an oral appliance warrants an objective assessment of the effective use and compliance with overnight oral appliance treatment for obstructive sleep apnea," said Vanderveken.
This abstract will receive the Clinical Excellence Award and Clinical Research Award at the AADSM 20th Anniversary Meeting.
###
The AADSM 20th Anniversary Meeting will bring together nearly 800 international clinicians and researchers in dental sleep medicine to present and discuss new findings and developments related to sleep-related breathing disorders, including obstructive sleep apnea (OSA), upper-airway resistance syndrome (UARS), and primary snoring. This three-day scientific meeting will be held in conjunction with SLEEP 2011, a joint venture of the American Academy of Sleep Medicine and the Sleep Research Society, in Minneapolis, Minn.
Abstract Title: Comparison of Subjective and Objective Measures of Oral Appliance Compliance During Treatment of Sleep-Disordered Breathing.
Presentation Date: Saturday, June 11, 2011
Category: Clinical Excellence Award and Clinical Research Award
Abstract ID: 013
END
ELSE PRESS RELEASES FROM THIS DATE:
2011-06-14
DARIEN, Ill. – According to new research that will be presented Saturday, June 11, at the 20th Anniversary Meeting of the American Academy of Dental Sleep Medicine (AADSM), the apnea-hypopnea index (AHI) in patients with severe obstructive sleep apnea (OSA) was more improved by a combination treatment of a mandibular advancement splint (MAS) and positive airway pressure (PAP) therapy than by continuous positive airway pressure (CPAP) therapy alone.
Results show that without lowering the pressure substantially, CPAP tolerance can be improved and severe OSA can be effectively ...
2011-06-14
DARIEN, Ill. – New research that will be presented Saturday, June 11, at the 20th Anniversary Meeting of the American Academy of Dental Sleep Medicine (AADSM) in Minneapolis, Minn., quantified the efficacy of mandibular advancement splints (MAS) using a self-administered, at-home device to monitor snoring and sleep-disordered breathing.
Clinical assessment of MAS efficacy in the treatment of snoring and obstructive sleep apnea (OSA) is based predominantly on subjective reports by the patient and partner, and less commonly, on the apnea hypopnea index (AHI), which is ...
2011-06-14
A new generation of high speed, silicon-based information technology has been brought a step closer by researchers in the Department of Electronic and Electrical Engineering at UCL and the London Centre for Nanotechnology. The team's research, published in next week's Nature Photonics journal, provides the first demonstration of an electrically driven, quantum dot laser grown directly on a silicon substrate (Si) with a wavelength (1300-nm) suitable for use in telecommunications.
Silicon is the most widely used material for the fabrication of active devices in electronics. ...
2011-06-14
Heart attack patients die at a higher rate when their nearest emergency room is so overtaxed that the ambulance transporting them is dispatched to another hospital, according to a new study led by scientists at the University of California, San Francisco.
The findings will be published online June 12, 2011 by JAMA, the Journal of the American Medical Association. The research also will be presented on June 13, 2011 at the AcademyHealth's annual research meeting in Seattle, WA.
"This is one of the first studies to tie patient-level outcomes to daily ambulance diversion ...
2011-06-14
The Aurora A kinase may contribute to polycystic kidney disease (PKD) by inactivating a key calcium channel in kidney cells, according to a study in the June 13 issue of The Journal of Cell Biology (www.jcb.org).
Aurora A is an oncogene best known as a regulator of mitotic progression. But the kinase has important functions during interphase as well, when it can promote cilia disassembly and can be activated by elevated calcium levels. Because both calcium signaling and cilia are defective in PKD, researchers from the Fox Chase Cancer Center in Philadelphia wondered whether ...
2011-06-14
A new study indicates high rates of injection drug use in urban Canadian Aboriginal youth, particularly in women, and points to the need for culturally specific prevention programs, states an article in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj101257.pdf
Aboriginal leadership is alarmed at the levels of substance abuse in their young people, especially injection drug use, which is associated with HIV and hepatitis C virus infections. Injection drug use accounts for 70%% of all hepatitis C virus and almost ...
2011-06-14
Administrative information can be useful for surveillance and understanding of alcohol-related harm in young people, states an article in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj110367.pdf
Binge drinking and overconsumption of alcohol by young people is a growing issue in many countries. For example, in a 2009 study, almost 60% of young Canadians aged 15-24 reported having consumed alcohol in the previous month, with 22% reporting heaving drinking and 20% experiencing harm related to alcohol consumption. In Australia, ...
2011-06-14
Accurate, safe prescribing information for children is often unavailable to doctors in Canada because pharmaceutical companies will not disclose information to Health Canada, states an editorial in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj110563.pdf
Health professionals in Canada as well as other countries such as Japan and Australia, unlike their colleagues in the United States and Europe, do not have access to the same body of evidence regarding pediatric dosing.
"As a consequence, Canadian children and youth ...
2011-06-14
NEW YORK – The U.S. Food and Drug Administration (FDA) has approved the first clinical trial in humans of a new technology: Cornell Dots, brightly glowing nanoparticles that can light up cancer cells in PET-optical imaging.
A paper describing this new medical technology, "Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma," will be published June 13, 2011 in the Journal of Clinical Investigation (July 2011). This is a collaboration between Memorial Sloan-Kettering Cancer Center (MSKCC), Cornell University, and Hybrid Silica ...
2011-06-14
PROVIDENCE, R.I. [Brown University] — A new Brown University computer analysis that predicts the effect of genetic mutations on how the body splices mRNA indicates as many as a third of disease-related mutations may be linked to splicing problems — more than double the proportion previously thought.
"Something like 85 percent of the mutations in the Human Gene Mutation Database are presumed to affect how proteins are coded, but what this work shows is that 22 percent of those are affecting the splicing process," said William Fairbrother, assistant professor of biology ...
LAST 30 PRESS RELEASES:
[Press-News.org] Study finds excellent agreement between subjective and objective compliance with OAT
Patients with obtrusive sleep apnea experience high rates of therapy compliance
